any holders ..any views ..looks to hve a great potential ...


Alltracel Pharmaceuticals Plc
06 April 2004


Alltracel Releases First Quarter 2004 Trading Update

-- First Quarter Revenue Grew 340% to 857k versus Q1 2003, and Company gives
Guidance for Q2--

-- SEALONTM Commences Marketing Support Programs as mdocTM Co-Brand
Partnership Program Continues to Expand--


April 06, 2004: Dublin, Ireland

Alltracel Pharmaceuticals Plc., (AIM: AP.L), the biopharmaceutical R&D company
specializing in medical devices and compounds and owner of the stops-bleeding m
docTM first-aid ingredient brand and SEALONTM - the consumer first-aid brand
featuring stops-bleeding as standard, is pleased to announce its first quarter
(Q1 2004) revenue was 857k, up 340% over first quarter 2003 revenues and more
than double last quarter's (Q4 2003) record revenue result.

Donal O'Brien Alltracel's Chief Operating Officer (COO) commented:

'As we expected Alltracel had a solid start to this year fuelled by strong SEAL
ONTM shipments in both the USA and UK on the back of last quarters trade listing
agreements and the start of our trade marketing program; as well as by continued
expansion in Europe of the mdocTM co-brand partnership program and the
commencement of shipments to Asia.

In addition to the previously announced co-brand partnership agreements with
retail and proprietary first aid brands across the EU, in this first quarter we
signed up 5 leading first-aid brands in Norway, Austria, Greece, Turkey and the
BeNeLux region to the mdocTM co-brand partnership program. This now brings to
32 to the number of brand partners in the program.

In this quarter we strengthened our global manufacturing capability with the
formal extension of our co-operation with our leading EU manufacturing partner
Chemopharma in the Czech Republic as well as with the appointment of Bangkok
based Neoplast Company Ltd. as our manufacturing and business development
partner for the Asia Pacific region.

Our first order for the Asia Pacific region already shipped in Q1.

To further secure our long term quality manufacturing capability, former
Hewlett-Packard and Loctite manufacturing executive Ciaran O' Reilly was
appointed as head of Manufacturing and Logistics and in this role he is
responsible for all manufacturing, product development, logistics and quality
standards in our own and partner facilities worldwide.

We saw an exciting breakthrough in our product development this quarter with the
successful development of a revolutionary new stops-bleeding product delivery
system - blottersTM. The blottersTM are small, thin, film strips (similar to
breath freshener strips) impregnated with mdocTM Alltracel's unique blood
stopping ingredient and are packed in a convenient pocket-sized plastic
dispenser. When placed on minor cuts e.g. shaving nicks blottersTM dissolve
after a few seconds releasing the mdocTM active ingredient and forming a soft
gel-like layer over the wound to stop the bleeding fast.

SEALONTM blottersTM have already been listed at Boots in the UK and are
expected to ship this quarter (Q2) followed by the introduction of Boots own
brand blottersTMsubsequently.

Our commercial focus this quarter remains on the start-up of SEALONTM consumer
marketing programs as well as further expansion of the mdocTM co-brand
partnership program primarily in the EU and Asia.

We are confident that this quarters revenue figure will be in the 1.0 to 1.2
million range.'

Alltracel Pharmaceuticals Plc., Tony Richardson, Chief Executive Officer of the Company, acquired 150,000 ordinary shares of euro;0.0125 each ("Ordinary Shares") on 17 April 2007. The Ordinary Shares were bought at pound;0.12 p each and following this acquisition, Mr Richardson now holds a total of 1,885,306 Ordinary Shares, which represents approximately 1.36 per cent of the Company's issued share capital.

The company share price has been moving up over the last few days. Full details on the company can be found at shareclubuk.co.uk The above news is just what I like to see as a share holder myself, Tony Richardson has faith in his own business a commitment that speaks volumes.

Noel Toolan, Chief Marketing Officer of Alltracel Pharmaceuticals Plc., has acquired 150,000 ordinary shares of euro;0.0125 each ("Ordinary Shares") on the 24 April 2007. The Ordinary Shares were bought at pound;0.135 p each and following this acquisition, Mr Toolan now holds a total of 150,000 Ordinary Shares, which represents approximately 0.115 per cent of the Company's issued share capital. Find out more at shareclubuk.co.uk.

This follows an announcement last week that Chief Executive Officer, Tony Richardson had acquired 150,000 shares in the company, he now holds 1,885,306 Ordinary Shares 1.36%.

Alltracel is set to enter the very lucrative international cosmenceuticals marketplace with their new product PhytopeuticsTM technology brand. My Wife and her friends spend a small fortune on skin care, I know this is a fact as I can just about find my after shave in the midst of all the skin repair kit, or polly-filler as I call them. Todays news is indeed first class, representing new sales area for the new sikn care proven product. The full report and other news on the company can be found at shareclubuk.co.uk.

Mr. Nick Hart joins AP. as CFO and executive director. Jan Dublin.
Your Say at shareclubuk.co,uk New product have to be marketed.